News

The UNIPRENEURS Initiative has recognized the entrepreneurial spirit of 20 professors, among them ECRC researcher Simone Spuler. As a co-founder of the startup MyoPax, she is pioneering stem cell technology to develop regenerative therapies for previously incurable muscle diseases.

The stem cell therapy developed by MyoPax, a spin-off from the Max Delbrück Center and Charité, could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process. The necessary clinical trial will start in the fall.

Michael Bader’s lab and six other European research groups are working to develop new methods to diagnose and monitor the progression of two kidney diseases. Both disorders are caused by an overactive unit of the body’s immune system. The researchers will receive €1.9 million for the project.

Sarah Hedtrich heads a guest group at the Max Delbrück Center. The Johanna Quandt Professor at the Berlin Institute of Health at Charité (BIH) is working on organ-on-a-chip models to develop new treatment options for rare hereditary and inflammatory skin and lung diseases.

The Robson lab at the Max Delbrück Center will be studying how the 3D structure of chromatin controls genes during development and in disease. Leveraging novel single cell methods, they will look at muscular dystrophies and retinal disease. Both seem to be linked to mutations that disrupt the function of non-coding DNA.

Two science communications projects of the Max Delbrück Center have received funding from the Stiftung Charité. About 100,000 Euro will go to Gary Lewin and illustrator Kat Menschik for a book on unusual animals in research, and to Russ Hodge and Jennifer von Schlichting for a board game on gene expression.

MyoPax develops regenerative therapies for previously incurable muscle diseases. An interview with co-founders Prof. Simone Spuler and Dr. Verena Schöwel-Wolf, now board member and CEO respectively

A group of international researchers – among them Stephan Mathas from the ECRC – has found that changing a single segment of the genome causes a previously unknown immunodeficiency in humans. The paper, which appears in Science Immunology, reports the discovery of a point mutation in the transcription factor IRF4.

The UK’s Physiological Society has named Gary Lewin an Honorary Fellow. Two Nobel Prize laureates in Physiology or Medicine also received the distinction. It is the highest honor that the tradition-rich society presents to an individual.

MyoPax, a new spin-off of the Max Delbrück Center and Charité, receives a 1.3 million euros loan to jump-start its entrepreneurial activities. The start-up develops regenerative therapies for previously incurable muscle diseases using its innovative muscle stem cell technology.